LOCUST WALK NEWS Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing […]
LOCUST WALK NEWS eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company
LOCUST WALK NEWS Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1,
LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option PHILADELPHIA
Podcast: Play in new window | Download (Duration: 11:03 — 25.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter,
2024 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Overview of AI in Biotech Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug
Podcast: Play in new window | Download (Duration: 35:36 — 81.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk’s Geoff Meyerson welcomes Kendalle Burlin O’Connell, Esq., CEO and President of MassBio, the nation’s pioneering biotechnology trade
Podcast: Play in new window | Download (Duration: 11:09 — 25.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: We invite you to
2023 Year-In-Review Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on